SandRidge Energy, Inc. SDOC
Our mention of SDOC in Friday’s premarket report turned out to very well-timed. We’ve had the stock on our radars since early this year, and pushed it to the back burner for awhile, having so many other items of interest on the table.
We circled back around to it on Friday, just in time to catch a solid single session performance as the stock ran from a low of a nickel up to .0674; that works out to a 35% intraday increase on fairly heavy volume.
We’ll continue to keep an eye on SDOC, which appears to be ready to gap-up slightly today, for a breach of the 50DMA at .08.
Celldex Therapeutics, Inc. CLDX
We’re going to tag CLDX this morning as a bottom-watch play with serious rebound potential. Our bottom-feeder alerts are sounding loudly as we’re seeing the stock take an absolute nosedive on news of the cancellation of the company’s late-stage brain tumor vaccine study.
We’re always on the lookout for knee-jerk selloffs (which often transition into recovery plays), and CLDX has lost roughly half its value solely on the perceived effect of the announcement.
It’s worth it to mention that the company still has seven clinical trials underway on other products, so the discontinued project is by no means the only thing in the company’s pipeline.
We’ll be interested to track the action in CLDX in coming sessions as investors adjust to this morning’s events.
Extended Watchlist:
DCLT, PVAH, GDPM, WRES, LNCO, BBEP, CLF, KEG